FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of FR901228 and to see how
well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the
growth of tumor cells by blocking the enzymes necessary for their growth